Multiple Successful Desensitizations to Brentuximab Vedotin in the Setting of Relapsed Peripheral T-Cell Lymphoma: Case Report.
作者信息
Rashid Alina R, Kuruvilla Philip
机构信息
, BScPhm, PharmD, ACPR, RPh, is with the Department of Pharmacy, William Osler Health System, Brampton, Ontario.
, MD, FRCPC, is with the Department of Hematology/Oncology, William Osler Health System, Brampton, Ontario.
出版信息
Can J Hosp Pharm. 2025 Jan 15;78(1):e3614. doi: 10.4212/cjhp.3614. eCollection 2025.
Abstract
摘要
相似文献
1
Multiple Successful Desensitizations to Brentuximab Vedotin in the Setting of Relapsed Peripheral T-Cell Lymphoma: Case Report.复发外周T细胞淋巴瘤患者对维布妥昔单抗多次成功脱敏：病例报告
Can J Hosp Pharm. 2025 Jan 15;78(1):e3614. doi: 10.4212/cjhp.3614. eCollection 2025.
2
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.自体移植后复发/难治性霍奇金淋巴瘤中维布妥昔单抗治疗：荟萃分析与历史数据对比
Curr Med Res Opin. 2015 May;31(5):993-1001. doi: 10.1185/03007995.2015.1030378. Epub 2015 Apr 9.
3
Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies.用于治疗复发或难治性恶性淋巴瘤的本妥昔单抗：前瞻性研究的系统评价和荟萃分析结果
Drug Des Devel Ther. 2015 Apr 21;9:2277-83. doi: 10.2147/DDDT.S83592. eCollection 2015.
4
Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.在指定患者计划中，本妥昔单抗治疗复发/难治性霍奇金淋巴瘤及复发/难治性系统性间变性大细胞淋巴瘤的经验：文献综述
Crit Rev Oncol Hematol. 2015 Sep;95(3):359-69. doi: 10.1016/j.critrevonc.2015.03.011. Epub 2015 Apr 27.
5
Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.复发/难治性霍奇金淋巴瘤的挽救治疗：同种异体移植、维布妥昔单抗及新型药物的作用
Expert Opin Biol Ther. 2016;16(3):347-64. doi: 10.1517/14712598.2015.1130821. Epub 2016 Feb 6.
6
Multiple successful desensitizations to brentuximab vedotin: a case report and literature review.多例成功的 Brentuximab vedotin 脱敏：病例报告及文献复习。
J Natl Compr Canc Netw. 2014 Apr;12(4):465-71. doi: 10.6004/jnccn.2014.0052.
7
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.本妥昔单抗维迪西妥单抗联合苯达莫司汀治疗复发或难治性霍奇金淋巴瘤的国际多中心单臂 1/2 期临床试验。
Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21.
8
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.用于治疗非霍奇金淋巴瘤的维布妥昔单抗：一项系统评价。
Crit Rev Oncol Hematol. 2017 Jan;109:42-50. doi: 10.1016/j.critrevonc.2016.11.009. Epub 2016 Nov 21.
9
Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.贝林妥欧单抗治疗霍奇金淋巴瘤的成本效益：系统评价。
Eur J Clin Pharmacol. 2023 Nov;79(11):1443-1452. doi: 10.1007/s00228-023-03557-6. Epub 2023 Sep 1.
10
Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.本妥昔单抗维迪西妥单抗在儿科间变大细胞淋巴瘤中的应用。
Front Immunol. 2023 May 18;14:1203471. doi: 10.3389/fimmu.2023.1203471. eCollection 2023.
本文引用的文献
1
Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma.在治疗难治性霍奇金淋巴瘤中，因严重过敏反应而对 Brentuximab vedotin 进行快速脱敏。
J Oncol Pharm Pract. 2021 Mar;27(2):505-508. doi: 10.1177/1078155220942292. Epub 2020 Jul 19.
2
Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue diseases.对用于癌症及炎症性或结缔组织疾病的单克隆抗体的过敏反应。
Ann Allergy Asthma Immunol. 2019 Jul;123(1):35-41. doi: 10.1016/j.anai.2019.04.015. Epub 2019 Apr 25.
3
Safety and Tolerability of Antibody-Drug Conjugates in Cancer.抗体药物偶联物在癌症中的安全性和耐受性。
Drug Saf. 2019 Feb;42(2):295-314. doi: 10.1007/s40264-018-0775-7.
4
Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies.癌症和慢性炎症性疾病中药物过敏和过敏反应的诊断和管理：紫杉烷和单克隆抗体的反应。
Clin Rev Allergy Immunol. 2018 Jun;54(3):375-385. doi: 10.1007/s12016-016-8556-5.
5
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies.快速药物脱敏治疗化疗和单克隆抗体的安全性、成本和疗效。
J Allergy Clin Immunol Pract. 2016 May-Jun;4(3):497-504. doi: 10.1016/j.jaip.2015.12.019. Epub 2016 Feb 16.
6
Hypersensitivity to biological agents-updated diagnosis, management, and treatment.生物制剂超敏反应——最新诊断、管理与治疗
J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):175-85; quiz 186. doi: 10.1016/j.jaip.2014.12.006.
7
Multiple successful desensitizations to brentuximab vedotin: a case report and literature review.多例成功的 Brentuximab vedotin 脱敏：病例报告及文献复习。
J Natl Compr Canc Netw. 2014 Apr;12(4):465-71. doi: 10.6004/jnccn.2014.0052.
8
Brentuximab vedotin.本妥昔单抗维迪西妥单抗。
MAbs. 2012 Jul-Aug;4(4):458-65. doi: 10.4161/mabs.20230. Epub 2012 Jul 1.
9
Rapid desensitization for hypersensitivity reactions to medications.药物超敏反应的快速脱敏治疗。
Immunol Allergy Clin North Am. 2009 Aug;29(3):585-606. doi: 10.1016/j.iac.2009.04.012.
10
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.溶酶体运输和半胱氨酸蛋白酶代谢通过肽连接的抗CD30-澳瑞他汀缀合物赋予靶标特异性细胞毒性。
J Biol Chem. 2006 Apr 14;281(15):10540-7. doi: 10.1074/jbc.M510026200. Epub 2006 Feb 16.
Zotero 插件